Siebels, M <br/><br/>
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.  [electronic resource] 

 -  World journal of urology  Feb 2011 
 - 121-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1433-8726 
<br/><br/><label>Standard No.: </label>10.1007/s00345-010-0570-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Renal Cell--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--adverse effects<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Recombinant Proteins<br/>Retrospective Studies<br/>Survival Rate<br/>Treatment Outcome